Navigation Links
Alexza Pharmaceuticals Completes End-of-Review Meeting With FDA for AZ-004 (Staccato® Loxapine) NDA
Date:1/18/2011

eview period will be 6 months.

The CRL also raised issues relating to the suitability of the stability studies undertaken by Alexza and certain other items relating to the Agency's pre-approval manufacturing inspection, which was completed in August 2010.  Alexza believes it understands these issues and that the issues can be adequately addressed in the AZ-004 NDA resubmission.

Since AZ-004 incorporates a novel delivery system, the CRL included input from FDA's Center for Devices and Radiological Health (CDRH).  In the CRL, CDRH requested a human factors study and related analysis to validate that the product can be used effectively in the proposed clinical setting.  Prior to the End-of-Review meeting, Alexza provided a human factors study draft protocol for review by CDRH, on which the FDA provided input and comments.  Alexza expects to finalize the protocol with the FDA and complete this study in the coming months.  Alexza is not required to conduct any additional efficacy or safety clinical trials.

CDRH also requested further bench testing of the product under an additional "worst-case" manufacturing scenario.  Alexza has completed this additional "worst-case" bench testing of the product, submitted data to the FDA and believes that this issue has been adequately addressed.

Conference Call Information

The Company will host an investor conference call and live webcast later today, Tuesday, January 18, 2011, at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time.  The conference call, live webcast and archived replay are open to all interested parties.

To access the conference call via the Internet, go to www.alexza.com, under the "Investor Relations" link.  Please join the call at least 15 minutes prior to the start of the call to ensure time for any software downloads that may be required.  Interested parties may also pre-regis
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Alexza Pharmaceuticals Provides Regulatory Update for AZ-004 (Staccato® Loxapine)
2. Alexza Pharmaceuticals Reports 2010 Third Quarter Financial Results and Provides Business Update
3. Alexza Pharmaceuticals to Announce 2010 Third Quarter Financial Results on November 9, 2010
4. Alexza Pharmaceuticals Reacquires U.S. and Canadian Rights for AZ-004 (Staccato® Loxapine)
5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
6. Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato® Loxapine) NDA
7. Alexzas Staccato® Nicotine Licensed to Cypress Bioscience
8. Alexza Pharmaceuticals to Present at Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference
9. Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
10. Alexza to Announce 2010 Second Quarter Financial Results on Monday, July 26, 2010
11. Alexza Pharmaceuticals Updates Staccato® Pipeline and Outlines Pipeline Development Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... LONDON , September 23, 2014 ... pharmaceutical assets, announces the appointment of Jarrod ... role, Mr Longcor is responsible for structuring, negotiating ... financial investments, as well as providing management and ... member of the Executive leadership team. ...
(Date:9/22/2014)... 2014 , Cloud technology ... rigor for trial master file (TMF) accessibility and completeness ... survey to date reveals an increase in the number ... with remote access to their electronic trial master file ... the Veeva 2014 Paperless TMF Survey: An ...
(Date:9/22/2014)... 22, 2014 Avanir Pharmaceuticals, Inc. (NASDAQ: ... to sell $200 million of its common stock in ... and BofA Merrill Lynch are acting as joint book-running ... a 30-day option to purchase additional shares of its ... in the offering are being sold by Avanir.  The ...
Breaking Medicine Technology:Avillion Appoints Jarrod Longcor as Chief Business Officer 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 3Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 4Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 3
(Date:9/23/2014)... UK and The Gambia, have developed a new approach ... direct sequencing of DNA extracted from sputum (a technique ... cause TB without the need for time-consuming culture of ... today in the peer-reviewed journal PeerJ ... Microbial Genomics at Warwick Medical School and Dr Martin ...
(Date:9/23/2014)... CA (PRWEB) September 23, 2014 On September ... arrival of the most technically advanced horticultural LED grow light ... again with the XL750 and XL1000 , ... well as the experienced horticulturalist, because it has what the ... light spectrum. Kind LED's grower-tested 12 band spectrum (also known ...
(Date:9/23/2014)... September 23, 2014 Eight-week program, “Healing Female ... neuralgia, and other chronic pelvic or sexual pain, teaching intuitive ... According to the Gallup poll, 1 in 7 women between ... pain. Many of those women suffer in silence, finding ... The type of pain varies from woman to woman ...
(Date:9/23/2014)... The Nordic Times is a Non-commercial Liberal ... a Danish media company based in the heart of ... news, blogs, social feeds, and original content covering politics, ... from around the world. , The Nordic Times focuses ... way that virality has changed and shaped journalism in ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 According to ... Tough Mudder team just completed the Pittsburg 2014 ... course event that helps fund the wounded warrior project. ... Mudder team member, the ”Tough Mudder is an endurance ... course. Designed and created by British Special Forces to ...
Breaking Medicine News(10 mins):Health News:Researchers develop new DNA sequencing method to diagnose tuberculosis 2Health News:Kind LED K5 Series XL1000 Grow Lights Sell Out in Only 2 Days 2Health News:Mind Body Expert Launches Pelvic Pain Relief Program 2Health News:Launching of The Nordic Times, a new online newspaper and aggregator. 2
... between the two illnesses , , TUESDAY, May 26 (HealthDay ... and heart disease has been discovered by German scientists. ... (CHD) has been known for years, but a genetic ... of Kiel team found that the two diseases share ...
... than issues such as depression, anxiety, study finds ... attention problems in kindergarten often struggle academically right through ... led by Joshua Breslau of the University of California, ... show how attention problems early in a child,s life ...
... Conference Call Scheduled for Monday June 1 at 1:00 ... SAN FRANCISCO, Calif., May 26 Sunesis Pharmaceuticals, Inc. ... on the development and commercialization of new oncology therapeutics, ... ongoing Phase 2 clinical trials in frontline acute myeloid ...
... HealthLeaders-InterStudy Analyze Healthcare Market Drivers for the Nation,s ... NASHVILLE, Tenn., May 26 HealthLeaders-InterStudy, ... reports that safety-net hospitals in Atlanta and Cleveland ... burdens by charging uninsured residents outside of certain ...
... notes importance of regular oral care to protect areas that ... a 2008 Gallup-Healthways poll(1) show that 42 percent of Hispanics ... even though the American Dental Association recommends having regular check-ups ... all Americans responded that they did not see a dentist ...
... integrate our internal applications more robustly and cost-effectively, but also ... new interfaces within our timelines. , ... ... APC, a regional, high volume, radiology group in Seattle, Washington, ...
Cached Medicine News:Health News:Gum Disease, Heart Disease Share Genetic Link 2Health News:Attention Problems in Kindergarten Could Spell Long-Term Academic Trouble 2Health News:Attention Problems in Kindergarten Could Spell Long-Term Academic Trouble 3Health News:Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO 2Health News:Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO 3Health News:Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO 4Health News:Recession Fallout Leads Safety-Net Hospitals to Charge Out-of-County Residents for Non-Emergency Services 2Health News:Hispanics Placing Their Oral Health at Risk by Cutting Back on Routine Dental Care 2Health News:Hispanics Placing Their Oral Health at Risk by Cutting Back on Routine Dental Care 3Health News:Seattle Radiologists Raise Workflow Performance and Results with Corepoint Integration Engine 2Health News:Seattle Radiologists Raise Workflow Performance and Results with Corepoint Integration Engine 3Health News:Seattle Radiologists Raise Workflow Performance and Results with Corepoint Integration Engine 4
Cold light source triple outlet....
Cold light source single outlet....
... 4150S is a state of ... light source with an integrated ... coupler to connect optical fiber ... distinguishes itself from all others ...
The 9300XSP is the brightest light source available. Visualize more clearly, see color more accurately, and work more effectively. Luxtecs xenon lighting delivers bright, white light that is as close...
Medicine Products: